SOX2 is an amplified lineage-survival oncogene in lung and esophageal squamous cell carcinomas

Adam J. Bass, Hideo Watanabe, Craig H. Mermel, Soyoung Yu, Sven Perner, Roel G. Verhaak, So Young Kim, Leslie Wardwell, Pablo Tamayo, Irit Gat-Viks, Alex H. Ramos, Michele S. Woo, Barbara A. Weir, Gad Getz, Rameen Beroukhim, Michael O'Kelly, Amit Dutt, Orit Rozenblatt-Rosen, Piotr Dziunycz, Justin KomisarofLucian R. Chirieac, Christopher J. Lafargue, Veit Scheble, Theresia Wilbertz, Changqing Ma, Shilpa Rao, Hiroshi Nakagawa, Douglas B. Stairs, Lin Lin, Thomas J. Giordano, Patrick Wagner, John D. Minna, Adi F. Gazdar, Chang Qi Zhu, Marcia S. Brose, Ivan Cecconello, Ulysses Ribeiro, Suely K. Marie, Olav Dahl, Ramesh A. Shivdasani, Ming Sound Tsao, Mark A. Rubin, Kwok K. Wong, Aviv Regev, William C. Hahn, David G. Beer, Anil K. Rustgi, Matthew Meyerson

The Nancy B. and Jake L. Hamon Center for Therapeutic Oncology Research
Internal Medicine
Pharmacology
Hamon Center For Therapeutic Oncology
Pathology

Research output: Contribution to journal › Article › peer-review

789 Scopus citations

Sort by
Weight
Alphabetically

SOX2 is an amplified lineage-survival oncogene in lung and esophageal squamous cell carcinomas

Fingerprint

Medicine & Life Sciences